Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma
Omid Hamid, MD, discusses the utility of tumor mutational burden as a biomarker for response to immunotherapy in patients with melanoma.
Website: https://www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive